Publicaciones en las que colabora con Luis Alou Cervera (52)

2024

  1. Comment on the article: In vivo Pharmacokinetics/Pharmacodynamics Profiles for Appropriate Doses of Cefditoren pivoxil against S. pneumoniae in Murine Lung-Infection Model

    Pharmaceutical Research

  2. Correction to: Comment on the article: In vivo Pharmacokinetics/Pharmacodynamics Profiles for Appropriate Doses of Cefditoren pivoxil against S. pneumoniae in Murine Lung-Infection Model (Pharmaceutical Research, (2024), 41, 8, (1595-1597), 10.1007/s11095-024-03729-8)

    Pharmaceutical Research

  3. Exploring therapeutic options for mild diabetic-related foot infections: a comparative in vitro study of cefditoren versus amoxicillin/clavulanic acid

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 4, pp. 356-359

2019

  1. Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains

    Journal of Global Antimicrobial Resistance, Vol. 19, pp. 241-251

2014

  1. Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress

    Journal of Neuroinflammation, Vol. 11

2013

  1. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 10, pp. 2291-2295

  2. Protection of Enterococcus faecalis in mixed cultures with carbapenemase-producing Escherichia coli and Bacteroide fragilis: effect of the bacterial load.

    Revista española de quimioterapia : publicación oficial de la Sociedad Española de Quimioterapia, Vol. 26, Núm. 3, pp. 220-225

  3. Stress-induced neuroinflammation: Role of the toll-like receptor-4 pathway

    Biological Psychiatry, Vol. 73, Núm. 1, pp. 32-43

2012

  1. Cefditoren and Ceftriaxone Enhance Complement-Mediated Immunity in the Presence of Specific Antibodies against Antibiotic-Resistant Pneumococcal Strains

    PLoS ONE, Vol. 7, Núm. 9

  2. In vitro interference of tigecycline at subinhibitory concentrations on biofilm development by Enterococcus faecalis

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 5, pp. 1155-1158

2011

  1. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24 h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate- resistant Staphylococcus aureus

    International Journal of Antimicrobial Agents, Vol. 37, Núm. 4, pp. 332-338

  2. Bacterial clearance from blood in mice infected by S. pneumoniae (penicillin MIC=16 mu g/ml) presenting specific IgG (non-protective levels) and treated with sub-therapeutic regimens of cefditoren (a highly bound cephalosporin)

    SCIENCE AND TECHNOLOGY AGAINST MICROBIAL PATHOGENS: RESEARCH, DEVELOPMENT AND EVALUATION

  3. Efficacy of simulated cefditoren versus amoxicillin-clavulanate free concentrations in countering intrastrain ftsI gene diffusion in Haemophilus influenzae

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 6, pp. 2788-2794

2010

  1. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2 μg/mL

    International Journal of Antimicrobial Agents, Vol. 35, Núm. 2, pp. 131-137

  2. Cefditoren versus ceftazidime in inducersubstrate combinations for the evaluation of AmpC production in a disc approximation test

    Revista Espanola de Quimioterapia, Vol. 23, Núm. 2, pp. 72-75

  3. Enhanced in vivo activity of cefditoren in preimmunized mice against penicillin-resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a sepsis model

    PLoS ONE, Vol. 5, Núm. 8

  4. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria

    International Journal of Antimicrobial Agents, Vol. 36, Núm. 2, pp. 137-144

  5. In vitro interference of β-lactams with biofilm development by prevalent community respiratory tract isolates

    International Journal of Antimicrobial Agents, Vol. 35, Núm. 3, pp. 274-277

  6. In vitro killing activity of crevicular concentrations of tinidazole plus common oral antibiotics against high-density mixed inocula of periodontal pathogens in strict anaerobic conditions

    Journal of Periodontology, Vol. 81, Núm. 1, pp. 131-138

  7. Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC

    Journal of Clinical Microbiology, Vol. 48, Núm. 6, pp. 2243-2246